Test Code CARNU Carnitine, Random, Urine
Reporting Name
Carnitine, UUseful For
Evaluation of patients with a clinical suspicion of a wide range of conditions including organic acidemias and fatty acid oxidation disorders
Monitoring carnitine treatment
Method Name
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
UrineSpecimen Required
Supplies: Urine Tubes, 10 mL (T068)
Container/Tube: Plastic, 10-mL urine tube
Specimen Volume: 1.5 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Frozen (preferred) | 365 days | |
Refrigerated | 72 hours |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
FREE CARNITINE:
77-214 nmol/mg of creatinine
TOTAL CARNITINE:
180-412 nmol/mg of creatinine
RATIO:
Acylcarnitine to free carnitine: 0.7-3.4
Day(s) Performed
Tuesday
CPT Code Information
82379
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
CARNU | Carnitine, U | 100428-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
27121 | Total | 17866-5 |
27122 | Free (FC) | 17867-3 |
15789 | AC/FC Ratio | 43576-8 |
21550 | Interpretation | 59462-2 |
Clinical Information
Carnitine and its esters are required for normal energy metabolism and serve 4 primary functions:
-Importing long-chain fatty acids into the mitochondria
-Exporting naturally occurring short-chain acyl-CoA groups from the mitochondria
-Maintaining the ratio of free CoA to esterified CoA
-Removing potentially toxic acyl-CoA groups from the cells and tissues
Evaluation of carnitine in serum, plasma, and urine is a biochemical screening test for suspected primary disorders of the carnitine cycle or for secondary disturbances in carnitine levels as a result of organic acidemias and fatty acid oxidation disorders. In the latter, acyl-CoA groups accumulate and are excreted into the urine and bile as carnitine derivatives, resulting in a secondary carnitine deficiency. More than 100 such primary and secondary disorders have been described. Collectively, their incidence is approximately 1 in 1000 live births. Primary carnitine deficiency has an incidence of approximately 1 in 21,000 live births based on Minnesota newborn screening data.
Other conditions that could cause an abnormal carnitine level include neuromuscular diseases, gastrointestinal disorders, familial cardiomyopathy, renal tubulopathies and chronic kidney failure (dialysis), and prolonged treatment with steroids, antibiotics (pivalic acid), anticonvulsants (valproic acid), and total parenteral nutrition.
Follow-up testing is required to differentiate primary and secondary carnitine deficiencies and to elucidate the exact cause.
Specimen Retention Time
1 monthTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Report Available
3 to 9 daysForms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.